PT217
- Generic Name
- PT217
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
PT217 is a bispecific Antibody against DLL3 and CD47
- Associated Conditions
- -
- Associated Therapies
- -
A Study of PT217 in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Phanes Therapeutics
- Target Recruit Count
- 203
- Registration Number
- NCT05652686
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath